Efficacy of clobazam monotherapy in three cases of symptomatic localization-related epilepsy in children

Author(s): Toshiyuki Iwasaki, Yutaka Nonoda, Kenji Takei, Nozomi Hosoda and Masahiro Ishii

Clobazam is approved in many countries as an additional antiepileptic drug for the management of intractable epilepsy. However, a number of reports have also described its use as first-line therapy in this indication. In this article, we describe three cases involving children (aged 2–12 years) with symptomatic localization-related and intractable epilepsy who responded to low dosage (0.2–0.4 mg/kg/day) clobazam monotherapy. For periods of 3.1–4.4 years, the treatment was well-tolerated and improved electroencephalogram findings with complete disappearance of clinical convulsions. Thus, low-dose clobazam appears to be a useful treatment option in these difficult-to-manage cases of intractable epilepsy.